Arcus Biosciences (RCUS) Q4 2025 earnings review
A Major Pipeline Pivot: Advancing HIF-2a While TIGIT Fades
Arcus is undergoing a dramatic strategic reversal. The company is rapidly winding down its once-lead TIGIT program (domvanalimab) in gastric cancer, effectively ending a major chapter of its Gilead partnership. However, the void is being aggressively filled by its HIF-2a inhibitor, casdatifan, which posted a compelling 15.1-month median progression-free survival (PFS) in kidney cancer. Financially, peak R&D spend appears to be in the rearview mirror; Q4 R&D dropped sequentially, and management is guiding for a meaningful expense deceleration in 2026. Armed with $1.0B in cash, Arcus has the runway to navigate this transition, but investors must now exclusively underwrite the casdatifan and early-stage inflammation pipelines.
🐂 Bull Case
With an updated 45.2% confirmed ORR and 15.1-month mPFS in the 100mg cohort, casdatifan is establishing a highly competitive profile in the $5B clear cell renal cell carcinoma (ccRCC) market.
Arcus ended 2025 with $1.0B in cash, providing a secure runway until the second half of 2028, completely removing near-term financing overhangs as R&D expenses begin to structurally decline.
🐻 Bear Case
The rapid wind-down of Phase 3 STAR-221 and Phase 2 EDGE-Gastric studies wipes out a massive portion of Arcus's formerly modeled commercial value. STAR-121 in lung cancer also faces a looming futility analysis.
Partner reimbursements dropped from $165M in 2024 to $127M in 2025. As Arcus takes on more fully-owned development programs, its standalone financial risk profile is increasing.
⚖️ Verdict: ⚪
Neutral. The pipeline reset is jarring but necessary. While the failure of the TIGIT trials destroys legacy value, the clinical data for casdatifan is genuinely strong, and the $1.0B cash position ensures Arcus survives to see its new thesis play out.
Key Themes
Casdatifan Accelerates Toward 1L Registration
The HIF-2a inhibitor is now the undisputed crown jewel. The 100mg daily cohort delivered a 45.2% confirmed ORR and 15.1-month mPFS. More importantly, management is executing a TKI-free strategy for first-line ccRCC, plotting a Phase 3 study for the end of 2026 utilizing combinations with zimberelimab or volrustomig. This represents an accelerating, high-conviction bet to displace standard-of-care TKIs.
Domvanalimab (TIGIT) Studies Reversing Course
The narrative around TIGIT has officially reversed. Arcus and Gilead are 'rapidly winding down' the Phase 3 STAR-221 and Phase 2 EDGE-Gastric trials. Furthermore, the Phase 3 STAR-121 lung cancer trial will undergo a futility analysis in the coming months. This marks a massive capital sunk cost and shifts all near-term commercial pressure onto casdatifan and quemliclustat.
Collaboration Revenue and Reimbursements Decelerating
While Arcus boasts a $1.0B cash pile, its partnership economics are shifting. Full-year gross reimbursements from Gilead fell 23% YoY to $127M. This specific data point contradicts the notion of a perfectly shielded balance sheet—Gilead is funding a smaller share of joint costs, leaving Arcus to shoulder the heavy financial lifting for its wholly-owned assets like casdatifan.
Emerging I&I Portfolio Diversification
Arcus is leveraging its small-molecule discovery engine to pivot into Inflammation and Immunology (I&I). An oral MRGPRX2 antagonist (targeting atopic dermatitis and urticaria) will enter the clinic in 2026, designed to avoid the exposure-limiting toxicities of competitors. An oral TNF inhibitor will follow in late 2026/early 2027. This introduces a completely new value vector outside of oncology.
Quemliclustat Quietly Advances
Lost in the noise of the TIGIT wind-down and the HIF-2a excitement is the small-molecule CD73 inhibitor, quemliclustat. The Phase 3 PRISM-1 trial in 1L pancreatic cancer completed enrollment in September 2025. With a readout expected in H1 2027, this represents a stable, albeit high-risk, wildcard for the company.
Other KPIs
R&D expense increased $10M YoY, driven by Phase 3 enrollment for casdatifan and quemliclustat. However, sequentially, it decelerated from $141M in Q3 and $139M in Q2. This signals that the peak trial start-up costs have passed, supporting management's guidance for lower R&D spend in 2026.
Accelerated from a $283M loss in FY24. The widening loss highlights the intense capital requirements of running simultaneous late-stage oncology trials, underscoring why the company raised $429M via equity in 2025.
Up sharply from 91.7 million shares in Q4 2024. The 29% share count dilution was the price paid for securing the $1.0B cash balance. Future clinical success will be spread across a significantly larger equity base.
Guidance
Reversing sharply. This implies an ~80% YoY decline from 2025's $247M. However, 2025 revenue was heavily inflated by a one-time $143M catch-up payment related to the etrumadenant license return. The $50M midpoint reflects a normalized run-rate of baseline collaboration services.
Reversing trend. After years of consecutive R&D expansion ($340M in 2023 -> $448M in 2024 -> $523M in 2025), spending will drop. The exact magnitude hinges on the upcoming futility analysis of the STAR-121 trial, which could trigger further trial closures and cost savings.
Stable and secure. This horizon safely bridges the company through all major upcoming catalysts: PEAK-1 readouts, PRISM-1 Phase 3 data (H1 2027), and the initiation of multiple Phase 1/Phase 3 trials in the new I&I and TKI-free RCC cohorts.
Key Questions
TIGIT Financial Unwind
With the winding down of STAR-221 and EDGE-Gastric, how much structural cost is removed from the 2026 R&D run-rate, and how much of that savings is being immediately reallocated to the planned 1L TKI-free casdatifan Phase 3?
STAR-121 Futility Outlook
Given the decision to wind down the gastric TIGIT trials, what is the internal confidence level heading into the STAR-121 lung cancer futility analysis? Is the 'meaningful decrease' in 2026 R&D guidance contingent on STAR-121 failing?
1L RCC Registration Strategy
You plan to present casdatifan + zimberelimab data in H2 2026 to form the backbone of your front-line strategy. What specific minimum threshold for primary progressive disease rates are you looking for to greenlight a full Phase 3 vs standard of care?